

# CLINUVEL

## ASX ANNOUNCEMENT

Melbourne, Australia, 6 August 2024

ASX: CUV | Börse Frankfurt: UR9 | ADR Level 1: CLVLY

## Change of Company Secretary

CLINUVEL advises that Ms Claire Newstead-Sinclair has been appointed Company Secretary, effective today, with Mr Peter Vaughan stepping down from the interim role.

Ms Newstead-Sinclair is a Chartered Accountant with over 20 years of experience in finance and governance roles. She joins CLINUVEL from Vistra Australia, where she provided company secretarial and CFO services to listed and unlisted companies, including roles with Paragon Care (ASX:PGC), Invion Limited (ASX:IVX), Mithril Resources Limited (ASX:MTH) and FAR Limited (ASX:FAR). Prior to this, Ms Newstead-Sinclair spent nine years with Cogstate (ASX:CGS) as Senior Finance Director and Company Secretary managing affairs across Australia and the USA. Ms Newstead-Sinclair holds a Bachelor of Business (Accounting) from Monash University. She has been a Chartered Accountant since 2005 and an Affiliated Member of the Governance Institute of Australia since 2012.

“As CLINUVEL expands, so too do the complexity of our business and governance obligations,” CLINUVEL’s Chair, Prof Jeffrey Rosenfeld said. “Over the last year we have grown our in-house expertise to ensure we continue to meet or exceed the exacting standards expected in global capital markets.

“With this long-term view, I am delighted to welcome Ms Newstead-Sinclair to CLINUVEL and look forward to working with her closely. I also thank Mr Vaughan on behalf of the Board for assuming interim secretarial responsibilities, which he now relinquishes to allow complete focus as CFO,” Prof Rosenfeld said.

Ms Newstead-Sinclair will be the person responsible for communications with the ASX in relation to Listing Rule matters under Listing Rule 12.6.

– END –

### About CLINUVEL PHARMACEUTICALS LIMITED

CLINUVEL (ASX: CUV; ADR LEVEL 1: CLVLY; Börse Frankfurt: UR9) is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialised populations. As pioneers in photomedicine and the family of melanocortin peptides, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, assisted DNA repair, repigmentation and acute or life-threatening conditions who lack alternatives.

CLINUVEL’s lead therapy, SCENESSE® (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the world’s first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore, and the USA. For more information, please go to <https://www.clinuvel.com>.

**Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTICALS LTD.**

### Head of Investor Relations

Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD

### Investor Enquiries

<https://www.clinuvel.com/investors/contact-us>

### Forward-Looking Statements

This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL's management. Statements may involve a number of known and unknown risks that could cause our future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialise pharmaceutical products; the COVID-19 pandemic and/or other world, regional or national events affecting the supply chain for a protracted period of time, including our ability to develop, manufacture, market and sell biopharmaceutical products; competition for our products, especially SCENESSE® (afamelanotide 16mg), PRÉNUMBRA® or NEURACTHEL®; our ability to achieve expected safety and efficacy results in a timely manner through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe, Israel, China and Japan of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE®, PRÉNUMBRA® or NEURACTHEL® which may lead to it being unable to supply its commercial markets and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology and consumer based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; our ability to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry and related industries; potential changes to tax liabilities or legislation; environmental risks; and other factors that have been discussed in our 2023 Annual Report. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation, outside of those required under applicable laws or relevant listing rules of the Australian Securities Exchange, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. More information on preliminary and uncertain forecasts and estimates is available on request, whereby it is stated that past performance is not an indicator of future performance.

### Contact:

Tel: +61 3 9660 4900

Fax: +61 3 9660 4909

Email: [mail@clinuvel.com](mailto:mail@clinuvel.com)

**Australia (Head Office)**, Level 22, 535 Bourke Street, Melbourne, Victoria, 3000, Australia

